ClinicalTrials.gg
CompletedNCT07946354Updated Nov 18, 2026

Atropine vs Hyoscine N-Butylbromide for CRBD

An interventional study of Atropine and Hyoscine N-butylbromide in Catheter-related Bladder Discomfort (CRBD), sponsored by Cantonal Hospital Zenica. Completed at 1 site in Bosnia and Herzegovina. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Cantonal Hospital Zenica · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 3 years after the study started (first participant enrolled Oct 2023, registered Nov 2026).
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Catheter-related bladder discomfort (CRBD) is a frequent postoperative complication associated with urinary catheterization. The purpose of this prospective, randomized, double-blind, placebo-controlled trial was to compare intravenous atropine, hyoscine N-butylbromide, and placebo for the prevention of CRBD in adults undergoing transurethral resection of the prostate or bladder tumors under general anesthesia.

The study interventions consisted of intravenous atropine 0.015 mg/kg, hyoscine N-butylbromide 20 mg, or an equivalent volume of 0.9% sodium chloride solution, administered approximately 10 minutes before completion of surgery.

The primary outcome was the presence of CRBD at one or more scheduled assessments at 1, 6, 12, and 24 hours after surgery. Secondary outcomes included CRBD severity assessed using a four-point categorical scale, postoperative pain intensity assessed using a 100-mm visual analogue scale, rescue analgesic and antiemetic requirements, and adverse effects assessed through clinical observation and participant report.

Read the detailed description

Study Design and Participants This prospective, randomized, double-blind, placebo-controlled, three-arm clinical trial was conducted between October 2023 and May 2025 in adult patients undergoing elective transurethral urological surgery under general anesthesia. Patients scheduled for transurethral resection of the prostate (TURP) or transurethral resection of bladder tumors (TURBT) requiring postoperative urinary catheterization were screened for eligibility. Patients with American Society of Anesthesiologists (ASA) physical status I or II were eligible for inclusion.

Exclusion criteria were a pre-existing indwelling urinary catheter, overactive bladder, neurogenic bladder, renal, hepatic, or cardiac insufficiency, clinically significant cardiac rhythm disorders, psychiatric disorders potentially interfering with postoperative assessment, known allergy or hypersensitivity to any study medication, and refusal to participate.

The study protocol was approved by the Ethics Committee of Cantonal Hospital Zenica (approval number: 00-03-35-1487-10/20). The study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants before enrollment.

Randomization and Blinding The random allocation sequence was computer-generated using block randomization with a 1:1:1 allocation ratio for the atropine, hyoscine N-butylbromide, and placebo groups. The sequence was prepared by an independent statistician without involvement in participant recruitment or postoperative outcome assessment.

Allocation concealment was maintained using sequentially numbered, opaque, sealed envelopes containing the treatment allocation corresponding to a numerical study code. Study solutions were prepared in visually identical syringes, labeled only with the corresponding identification number, and adjusted to the same final volume.

Participants and investigators responsible for postoperative outcome assessment and data collection were blinded to treatment allocation. Study solutions were prepared by personnel without involvement in postoperative assessment. The allocation code remained concealed from outcome assessors throughout data collection.

Study Interventions The atropine intervention consisted of atropine 0.015 mg/kg intravenously. The hyoscine N-butylbromide intervention consisted of hyoscine N-butylbromide 20 mg intravenously. The placebo intervention consisted of an equivalent volume of 0.9% sodium chloride solution intravenously.

All study preparations were diluted to the same final volume and administered using identical numbered syringes. The study solution was administered approximately 10 minutes before completion of the surgical procedure.

Anesthetic Management A standardized general anesthetic protocol was applied across all three groups. Standard intraoperative monitoring included continuous electrocardiography, non-invasive arterial blood pressure measurement, peripheral oxygen saturation, and capnography.

General anesthesia was induced with intravenous propofol 2 mg/kg, fentanyl 2 μg/kg, and atracurium 0.5 mg/kg. Endotracheal intubation was performed following adequate neuromuscular blockade, and controlled mechanical ventilation was initiated. Anesthesia was maintained with sevoflurane, with additional fentanyl and atracurium administered when clinically indicated. Mechanical ventilation was adjusted to maintain end-tidal carbon dioxide within the physiological range.

No pharmacological reversal of neuromuscular blockade was administered. Extubation was performed after spontaneous recovery from neuromuscular blockade, assessed using clinical criteria.

Urinary Catheterization Urinary catheterization was performed according to the standard institutional urological protocol. Foley catheters sized 18, 20, or 22 Ch/Fr were selected according to surgical and clinical requirements. Catheter size was documented for each participant. The catheter balloon was inflated with 10 mL of sterile water, and the urinary catheter remained in situ throughout the 24-hour postoperative observation period.

Outcome Measures The primary outcome was the presence of catheter-related bladder discomfort (CRBD) at one or more scheduled assessments at 1, 6, 12, and 24 hours after surgery. CRBD incidence was also assessed separately at each scheduled time point.

Secondary outcomes included CRBD severity, postoperative surgical pain intensity, requirement for rescue analgesia, additional analgesic consumption, requirement for rescue antiemetic therapy, and incidence of predefined adverse effects.

Postoperative assessments were performed at 1, 6, 12, and 24 hours after surgery by investigators blinded to treatment allocation.

Assessment of Catheter-Related Bladder Discomfort CRBD was assessed separately from postoperative surgical pain. Assessment included suprapubic or urethral discomfort, urinary urgency, burning sensation, and a persistent sensation of needing to void despite a functioning urinary catheter.

The presence or absence of CRBD was recorded at each assessment. CRBD severity was assessed using a four-point categorical severity scale:

None: absence of catheter-related discomfort. Mild: catheter-related discomfort reported only after direct questioning. Moderate: catheter-related discomfort reported spontaneously without prompting. Severe: spontaneous catheter-related discomfort accompanied by behavioral manifestations, including facial expression of distress, vocalization, restlessness, or adoption of a forced position because of discomfort.

CRBD severity was treated as an ordinal outcome for statistical analysis.

Assessment of Postoperative Pain and Rescue Analgesia Postoperative surgical pain was evaluated separately from CRBD at 1, 6, 12, and 24 hours after surgery using a 100-mm visual analogue scale (VAS). A score of 0 mm represented no pain, and a score of 100 mm represented the worst imaginable pain.

VAS scores were recorded before administration of rescue analgesia at each scheduled assessment. According to the predefined protocol, scores of 0-10 mm represented no or minimal pain, >10-30 mm mild pain, >30-70 mm moderate pain, and >70-100 mm severe pain.

Rescue analgesia was administered for a VAS score exceeding 30 mm or at the participant's request. Initial rescue analgesia consisted of tramadol 100 mg intravenously. An additional 25 mg of intravenous tramadol was administered for persistent pain with a VAS score exceeding 50 mm. Rescue analgesia requirements and additional analgesic administration were documented for each participant.

Assessment of Adverse Effects Predefined adverse effects were assessed through clinical observation and participant report at 1, 6, 12, and 24 hours after surgery. Assessments included dry mouth, facial flushing, blurred vision, nausea, and vomiting. Each adverse event was recorded as present or absent.

Dry mouth, facial flushing, and blurred vision were classified as potential antimuscarinic adverse effects. Nausea and vomiting were recorded as postoperative adverse events.

The composite outcome of any antimuscarinic adverse effect was defined as the occurrence of dry mouth, facial flushing, or blurred vision at one or more scheduled assessments. Each participant was counted once for this composite outcome, regardless of the number of symptoms or affected assessment time points.

Rescue antiemetic therapy consisted of ondansetron 4 mg intravenously for postoperative nausea or vomiting requiring treatment. Receipt of rescue antiemetic therapy during the first 24 postoperative hours was recorded for each participant.

02

Conditions studied

  • Catheter-related Bladder Discomfort (CRBD)

Keywords

  • muscarinic antagonists
  • postoperative complications
  • treatment outcome
  • urinary catheterization
  • urological surgical procedures
03

In context

Postoperative Complications

1,338 studies on the registry are indexed under Postoperative Complications; 311 are open to participants now.

This study's enrollment of 90 is below the median of 114 across 770 interventional studies indexed under Postoperative Complications.

Browse Postoperative Complications studies →

Lead sponsor

Cantonal Hospital Zenica is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients scheduled for transurethral resection of the prostate (TURP) or transurethral resection of bladder tumors (TURBT) who required postoperative urinary catheterization were screened for eligibility.
  • Patients with an (ASA) physical status I or II.

Exclusion criteria

Exclusion Criteria:

  • pre-existing indwelling urinary catheter,
  • overactive bladder,
  • neurogenic bladder,
  • renal, hepatic, or cardiac insufficiency,
  • cardiac rhythm disorders,
  • psychiatric disorders that could interfere with postoperative assessment,
  • known allergy or to any medication used in the study, and
  • refusal to participate.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Atropine

    30 adults undergoing transurethral resection of the prostate or bladder tumor were allocated to receive intravenous atropine 0.015 mg/kg

    Drug: Atropine

  • Experimental
    Hyoscine N-Butylbromide

    30 adults undergoing transurethral resection of the prostate or bladder tumor were allocated to receive intravenous hyoscine N-butylbromide 20 mg

    Drug: Hyoscine N-butylbromide

  • Placebo comparator
    Placebo

    30 adults undergoing transurethral resection of the prostate or bladder tumor were allocated to receive intravenous saline

    Drug: Placebo

Interventions

  • 30 adults undergoing transurethral resection of the prostate or bladder tumor were allocated to receive intravenous atropine 0.015 mg/kg

  • DrugButylscopolammonium BromideStudies of Butylscopolammonium BromideButylscopolammonium Bromide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    30 adults undergoing transurethral resection of the prostate or bladder tumor were allocated to receive intravenous hyoscine N-butylbromide 20 mg

  • DrugPlacebo

    30 adults undergoing transurethral resection of the prostate or bladder tumor were allocated to receive intravenous saline

06

What researchers measure

Primary outcomes

  1. Severity of Catheter-Related Bladder Discomfort (CRBD) Assessed Using a Four-Point CRBD Severity Scale

    Time frame: 1 hour

Secondary outcomes

  1. Postoperative Pain Intensity Assessed Using the Visual Analogue Scale (VAS)

    Time frame: 24 hours postoperative

  2. Incidence of Adverse Effects Assessed by Clinical Observation and Patient Self-Report

    Time frame: 24 hours postoperative

07

Study locations

1 site
  • CH Zenica
    Zenica, 72000, Bosnia and Herzegovina
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in May 2025, 18 months.

Of 395 non-industry interventional studies with no phase under Postoperative Complications, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 44. This study's 18 months is close to that.

Counting every sponsor, half of 399 studies reached it within 20 months; a quarter within 8 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 18, 2026
StartActual
Oct 20, 2023
Primary completionActual
May 15, 2025
CompletionActual
May 15, 2025
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07946354
Lead sponsor
Cantonal Hospital Zenica
Responsible party
Mirza Kovacevic (Clinical Professor, Cantonal Hospital Zenica) — Principal investigator
First posted
Nov 18, 2026
Start date
Oct 20, 2023
Primary completion
May 15, 2025
Completion
May 15, 2025
Last update
Nov 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atropine · Butylscopolammonium Bromide

Start the discussion